Xie W, Chu Q, Brea L, Zeng G, et al. EZH2 PROTACs outperform catalytic inhibitors in prostate cancer by targeting a methylation-independent function of PRC2. Oncogene 2026 Jan 7. doi: 10.1038/s41388-025-03662.
PMID: 41501210